Pyrimide 3-Way Combination Drench for Sheep
Pharm Smart Australia Pty Ltd

Chemwatch Hazard Alert Code: **3**

Chemwatch: **5489-01**
Version No: **2.1.13.9**
Safety Data Sheet according to WHS Regulations (Hazardous Chemicals) Amendment 2020 and ADG requirements

Issue Date: **17/08/2021**
Print Date: **18/08/2021**
L.GHS.AUS.EN

SECTION 1 Identification of the substance / mixture and of the company / undertaking

Product Identifier

Product name	Pyrimide 3-Way Combination Drench for Sheep
Chemical Name	Not Applicable
Synonyms	APVMA Code: 62099
Proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (contains albendazole and abamectin)
Chemical formula	Not Applicable
Other means of identification	Not Available

Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	For the treatment and control of gastrointestinal parasites in sheep, including those with single or dual resistance to avermectin/milbemycin, benzimidazole or levamisole/morantel drug families. Effective against lungworm, itchmite and nasal bot (larval stages) of sheep and provides a selenium and cobalt supplement.

Details of the supplier of the safety data sheet

Registered company name	**Pharm Smart Australia Pty Ltd**
Address	Suite 11, Level 1, 240 Waterworks Road Ashgrove QLD 4060 Australia
Telephone	1800 979 692
Fax	Not Available
Website	www.pharmsmart.com.au
Email	info@pharmsmart.com.au

Emergency telephone number

Association / Organisation	**Pharm Smart Australia Pty Ltd**
Emergency telephone numbers	**1800 979 692 (Mon-Fri 9-5pm)**
Other emergency telephone numbers	**Not Available**

SECTION 2 Hazards identification

Classification of the substance or mixture

HAZARDOUS CHEMICAL. DANGEROUS GOODS. According to the WHS Regulations and the ADG Code.

Poisons Schedule	S6
Classification [1]	Acute Toxicity (Oral) Category 4, Sensitisation (Skin) Category 1, Germ Cell Mutagenicity Category 2, Reproductive Toxicity Category 1B, Hazardous to the Aquatic Environment Long-Term Hazard Category 1
Legend:	*1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI*

Label elements

Hazard pictogram(s)	
Signal word	**Danger**

Hazard statement(s)

H302	Harmful if swallowed.
H317	May cause an allergic skin reaction.
H341	Suspected of causing genetic defects.
H360D	May damage the unborn child.
H410	Very toxic to aquatic life with long lasting effects.

Precautionary statement(s) Prevention

Page 1 continued...

P201	Obtain special instructions before use.
P280	Wear protective gloves and protective clothing.
P261	Avoid breathing mist/vapours/spray.
P264	Wash all exposed external body areas thoroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P273	Avoid release to the environment.
P272	Contaminated work clothing should not be allowed out of the workplace.

Precautionary statement(s) Response

P308+P313	IF exposed or concerned: Get medical advice/ attention.
P302+P352	IF ON SKIN: Wash with plenty of water.
P333+P313	If skin irritation or rash occurs: Get medical advice/attention.
P362+P364	Take off contaminated clothing and wash it before reuse.
P391	Collect spillage.
P301+P312	IF SWALLOWED: Call a POISON CENTER/doctor/physician/first aider if you feel unwell.
P330	Rinse mouth.

Precautionary statement(s) Storage

P405	Store locked up.

Precautionary statement(s) Disposal

P501	Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.

SECTION 3 Composition / information on ingredients

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name
Not Available		Levamisole as
16595-80-5	1-10	levamisole hydrochloride
54965-21-8	1-10	albendazole
15137-09-4	<1	EDTA cobalt disodium salt
71751-41-2	<1	abamectin
Not Available		selenium as
13410-01-0	<1	sodium selenate, anhydrous
Not Available	balance	Ingredients determined not to be hazardous
Legend:	*1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L; * EU IOELVs available*	

SECTION 4 First aid measures

Description of first aid measures

Eye Contact	If this product comes in contact with the eyes: ▸ Wash out immediately with fresh running water. ▸ Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. ▸ Seek medical attention without delay; if pain persists or recurs seek medical attention. ▸ Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.
Skin Contact	If skin contact occurs: ▸ Immediately remove all contaminated clothing, including footwear. ▸ Flush skin and hair with running water (and soap if available). ▸ Seek medical attention in event of irritation.
Inhalation	▸ If fumes, aerosols or combustion products are inhaled remove from contaminated area. ▸ Other measures are usually unnecessary.
Ingestion	▸ **IF SWALLOWED, REFER FOR MEDICAL ATTENTION, WHERE POSSIBLE, WITHOUT DELAY.** ▸ For advice, contact a Poisons Information Centre or a doctor. ▸ Urgent hospital treatment is likely to be needed. ▸ In the mean time, qualified first-aid personnel should treat the patient following observation and employing supportive measures as indicated by the patient's condition. ▸ If the services of a medical officer or medical doctor are readily available, the patient should be placed in his/her care and a copy of the SDS should be provided. Further action will be the responsibility of the medical specialist. ▸ If medical attention is not available on the worksite or surroundings send the patient to a hospital together with a copy of the SDS. **Where medical attention is not immediately available or where the patient is more than 15 minutes from a hospital or unless instructed otherwise:** ▸ **INDUCE** vomiting with fingers down the back of the throat, **ONLY IF CONSCIOUS**. Lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration.

Continued...

	NOTE: Wear a protective glove when inducing vomiting by mechanical means.

Indication of any immediate medical attention and special treatment needed

As in all cases of suspected poisoning, follow the ABCDEs of emergency medicine (airway, breathing, circulation, disability, exposure), then the ABCDEs of toxicology (antidotes, basics, change absorption, change distribution, change elimination).
For poisons (where specific treatment regime is absent):

BASIC TREATMENT

- Establish a patent airway with suction where necessary.
- Watch for signs of respiratory insufficiency and assist ventilation as necessary.
- Administer oxygen by non-rebreather mask at 10 to 15 L/min.
- Monitor and treat, where necessary, for pulmonary oedema.
- Monitor and treat, where necessary, for shock.
- Anticipate seizures.
- **DO NOT** use emetics. Where ingestion is suspected rinse mouth and give up to 200 ml water (5 ml/kg recommended) for dilution where patient is able to swallow, has a strong gag reflex and does not drool.

ADVANCED TREATMENT

- Consider orotracheal or nasotracheal intubation for airway control in unconscious patient or where respiratory arrest has occurred.
- Positive-pressure ventilation using a bag-valve mask might be of use.
- Monitor and treat, where necessary, for arrhythmias.
- Start an IV D5W TKO. If signs of hypovolaemia are present use lactated Ringers solution. Fluid overload might create complications.
- Drug therapy should be considered for pulmonary oedema.
- Hypotension with signs of hypovolaemia requires the cautious administration of fluids. Fluid overload might create complications.
- Treat seizures with diazepam.
- Proparacaine hydrochloride should be used to assist eye irrigation.

BRONSTEIN, A.C. and CURRANCE, P.L.
EMERGENCY CARE FOR HAZARDOUS MATERIALS EXPOSURE: 2nd Ed. 1994
Treat symptomatically.
For abamectin (avermectins):
Toxicity following accidental ingestion may be minimised by emesis-induction within one half hour of exposure. Since abamectin is thought to bind to glutamate-gated chloride ion channels, it is probably wise to avoid drugs that also interact with other ligand-gated chloride channels, including those that enhance GABA activity in patients with potentially toxic abamectin exposure
Avoid drugs that enhance GABA activity (barbiturate, benzodiazepines, valproic acid, etc.).
After albendazole is administered, intestinal and hepatic albendazole metabolism leads to albendazole sulfoxide (active metabolite) and albendazole sulfone (inactive metabolite) formation. The metabolism albendazole sulfoxide effects as the active substance against the worms, albendazole sulfone has no active affection

SECTION 5 Firefighting measures

Extinguishing media

The product contains a substantial proportion of water, therefore there are no restrictions on the type of extinguishing media which may be used. Choice of extinguishing media should take into account surrounding areas.
Though the material is non-combustible, evaporation of water from the mixture, caused by the heat of nearby fire, may produce floating layers of combustible substances.
In such an event consider:
- foam.
- dry chemical powder.
- carbon dioxide.

Special hazards arising from the substrate or mixture

Fire Incompatibility	None known.

Advice for firefighters

Fire Fighting	- Alert Fire Brigade and tell them location and nature of hazard. - Wear breathing apparatus plus protective gloves in the event of a fire. - Prevent, by any means available, spillage from entering drains or water courses. - Use fire fighting procedures suitable for surrounding area. - **DO NOT** approach containers suspected to be hot. - Cool fire exposed containers with water spray from a protected location. - If safe to do so, remove containers from path of fire. - Equipment should be thoroughly decontaminated after use.
Fire/Explosion Hazard	- The material is not readily combustible under normal conditions. - However, it will break down under fire conditions and the organic component may burn. - Not considered to be a significant fire risk. - Heat may cause expansion or decomposition with violent rupture of containers. - Decomposes on heating and may produce toxic fumes of carbon monoxide (CO). - May emit acrid smoke. Decomposes on heating and produces toxic fumes of: carbon dioxide (CO_2) nitrogen oxides (NO_x) metal oxides other pyrolysis products typical of burning organic material.
HAZCHEM	•3Z

SECTION 6 Accidental release measures

Personal precautions, protective equipment and emergency procedures

Continued...

See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up

Minor Spills	Environmental hazard - contain spillage. ▸ Clean up all spills immediately. ▸ Avoid breathing vapours and contact with skin and eyes. ▸ Control personal contact with the substance, by using protective equipment. ▸ Contain and absorb spill with sand, earth, inert material or vermiculite. ▸ Wipe up. ▸ Place in a suitable, labelled container for waste disposal.
Major Spills	▸ Clear area of personnel and move upwind. ▸ Alert Fire Brigade and tell them location and nature of hazard. ▸ Wear breathing apparatus plus protective gloves. ▸ Prevent, by any means available, spillage from entering drains or water course. ▸ Stop leak if safe to do so. ▸ Contain spill with sand, earth or vermiculite. ▸ Collect recoverable product into labelled containers for recycling. ▸ Neutralise/decontaminate residue (see Section 13 for specific agent). ▸ Collect solid residues and seal in labelled drums for disposal. ▸ Wash area and prevent runoff into drains. ▸ After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using. ▸ If contamination of drains or waterways occurs, advise emergency services. Environmental hazard - contain spillage.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

Precautions for safe handling

Safe handling	▸ **DO NOT** allow clothing wet with material to stay in contact with skin ▸ Avoid all personal contact, including inhalation. ▸ Wear protective clothing when risk of exposure occurs. ▸ Use in a well-ventilated area. ▸ Avoid contact with moisture. ▸ Avoid contact with incompatible materials. ▸ When handling, **DO NOT** eat, drink or smoke. ▸ Keep containers securely sealed when not in use. ▸ Avoid physical damage to containers. ▸ Always wash hands with soap and water after handling. ▸ Work clothes should be laundered separately. Launder contaminated clothing before re-use. ▸ Use good occupational work practice. ▸ Observe manufacturer's storage and handling recommendations contained within this SDS. ▸ Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.
Other information	▸ Store in original containers. ▸ Keep containers securely sealed. ▸ Store in a cool, dry, well-ventilated area. ▸ Store away from incompatible materials and foodstuff containers. ▸ Protect containers against physical damage and check regularly for leaks. ▸ Observe manufacturer's storage and handling recommendations contained within this SDS.

Conditions for safe storage, including any incompatibilities

Suitable container	▸ Polyethylene or polypropylene container. ▸ Packing as recommended by manufacturer. ▸ Check all containers are clearly labelled and free from leaks.
Storage incompatibility	Avoid contamination of water, foodstuffs, feed or seed.

SECTION 8 Exposure controls / personal protection

Control parameters

Occupational Exposure Limits (OEL)

INGREDIENT DATA

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
Australia Exposure Standards	sodium selenate, anhydrous	Selenium compounds (as Se) excluding hydrogen selenide	0.1 mg/m3	Not Available	Not Available	Not Available

Emergency Limits

Ingredient	TEEL-1	TEEL-2	TEEL-3
sodium selenate, anhydrous	1.4 mg/m3	1.6 mg/m3	2 mg/m3

Ingredient	Original IDLH	Revised IDLH
levamisole hydrochloride	Not Available	Not Available
albendazole	Not Available	Not Available
EDTA cobalt disodium salt	Not Available	Not Available

Continued...

Ingredient	Original IDLH	Revised IDLH
abamectin	Not Available	Not Available
sodium selenate, anhydrous	1 mg/m3	Not Available

Occupational Exposure Banding

Ingredient	Occupational Exposure Band Rating	Occupational Exposure Band Limit
levamisole hydrochloride	E	≤ 0.01 mg/m³
albendazole	E	≤ 0.01 mg/m³
EDTA cobalt disodium salt	E	≤ 0.01 mg/m³
abamectin	E	≤ 0.01 mg/m³
Notes:	*Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a range of exposure concentrations that are expected to protect worker health.*	

MATERIAL DATA

Exposure controls

Appropriate engineering controls

Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection.
The basic types of engineering controls are:
Process controls which involve changing the way a job activity or process is done to reduce the risk.
Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use.
Employers may need to use multiple types of controls to prevent employee overexposure.

General exhaust is adequate under normal operating conditions. If risk of overexposure exists, wear SAA approved respirator. Correct fit is essential to obtain adequate protection. Provide adequate ventilation in warehouse or closed storage areas. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant.

Type of Contaminant:	Air Speed:
solvent, vapours, degreasing etc., evaporating from tank (in still air)	0.25-0.5 m/s (50-100 f/min)
aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray drift, plating acid fumes, pickling (released at low velocity into zone of active generation)	0.5-1 m/s (100-200 f/min.)
direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active generation into zone of rapid air motion)	1-2.5 m/s (200-500 f/min)
grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of very high rapid air motion).	2.5-10 m/s (500-2000 f/min.)

Within each range the appropriate value depends on:

Lower end of the range	Upper end of the range
1: Room air currents minimal or favourable to capture	1: Disturbing room air currents
2: Contaminants of low toxicity or of nuisance value only	2: Contaminants of high toxicity
3: Intermittent, low production.	3: High production, heavy use
4: Large hood or large air mass in motion	4: Small hood - local control only

Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2 m/s (200-400 f/min.) for extraction of solvents generated in a tank 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used.

Personal protection



Eye and face protection

- Safety glasses with side shields.
- Chemical goggles.
- Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent]

Skin protection

See Hand protection below

Hands/feet protection

- Wear chemical protective gloves, e.g. PVC.
- Wear safety footwear or safety gumboots, e.g. Rubber

NOTE:

- The material may produce skin sensitisation in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact.
- Contaminated leather items, such as shoes, belts and watch-bands should be removed and destroyed.

The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to

Continued...

	manufacturer. Where the chemical is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application. The exact break through time for substances has to be obtained from the manufacturer of the protective gloves and has to be observed when making a final choice. Personal hygiene is a key element of effective hand care. Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended. Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include: · frequency and duration of contact, · chemical resistance of glove material, · glove thickness and · dexterity Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739, AS/NZS 2161.1 or national equivalent). · When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended. · When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended. · Some glove polymer types are less affected by movement and this should be taken into account when considering gloves for long-term use. · Contaminated gloves should be replaced. As defined in ASTM F-739-96 in any application, gloves are rated as: · Excellent when breakthrough time > 480 min · Good when breakthrough time > 20 min · Fair when breakthrough time < 20 min · Poor when glove material degrades For general applications, gloves with a thickness typically greater than 0.35 mm, are recommended. It should be emphasised that glove thickness is not necessarily a good predictor of glove resistance to a specific chemical, as the permeation efficiency of the glove will be dependent on the exact composition of the glove material. Therefore, glove selection should also be based on consideration of the task requirements and knowledge of breakthrough times. Glove thickness may also vary depending on the glove manufacturer, the glove type and the glove model. Therefore, the manufacturers' technical data should always be taken into account to ensure selection of the most appropriate glove for the task. Note: Depending on the activity being conducted, gloves of varying thickness may be required for specific tasks. For example: · Thinner gloves (down to 0.1 mm or less) may be required where a high degree of manual dexterity is needed. However, these gloves are only likely to give short duration protection and would normally be just for single use applications, then disposed of. · Thicker gloves (up to 3 mm or more) may be required where there is a mechanical (as well as a chemical) risk i.e. where there is abrasion or puncture potential Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.
Body protection	See Other protection below
Other protection	▸ Overalls. ▸ P.V.C apron. ▸ Barrier cream. ▸ Skin cleansing cream. ▸ Eye wash unit.

Respiratory protection

Type A Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

- Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content.
- The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.
- Cartridge performance is affected by humidity. Cartridges should be changed after 2 hr of continuous use unless it is determined that the humidity is less than 75%, in which case, cartridges can be used for 4 hr. Used cartridges should be discarded daily, regardless of the length of time used

SECTION 9 Physical and chemical properties

Information on basic physical and chemical properties

Appearance	Opaque pink to bluish-pink liquid with no characteristic odour; mixes with water.

Physical state	Liquid	**Relative density (Water = 1)**	0.98-1.02 @20C
Odour	Not Available	**Partition coefficient n-octanol / water**	Not Available
Odour threshold	Not Available	**Auto-ignition temperature (°C)**	Not Applicable
pH (as supplied)	~4.0	**Decomposition temperature**	Not Available
Melting point / freezing point (°C)	~0	**Viscosity (cSt)**	Not Available
Initial boiling point and boiling range (°C)	~100	**Molecular weight (g/mol)**	Not Applicable
Flash point (°C)	Not Applicable	**Taste**	Not Available
Evaporation rate	Not Available	**Explosive properties**	Not Available
Flammability	Not Applicable	**Oxidising properties**	Not Available
Upper Explosive Limit (%)	Not Applicable	**Surface Tension (dyn/cm or mN/m)**	Not Available
Lower Explosive Limit (%)	Not Applicable	**Volatile Component (%vol)**	Not Available
Vapour pressure (kPa)	2.37 @20C	**Gas group**	Not Available
Solubility in water	Miscible	**pH as a solution (%)**	Not Available
Vapour density (Air = 1)	Not Available	**VOC g/L**	Not Available

Continued...

SECTION 10 Stability and reactivity

Reactivity	See section 7
Chemical stability	▸ Unstable in the presence of incompatible materials. ▸ Product is considered stable. ▸ Hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

SECTION 11 Toxicological information

Information on toxicological effects

Inhaled	The material is not thought to produce either adverse health effects or irritation of the respiratory tract following inhalation (as classified by EC Directives using animal models). Nevertheless, adverse systemic effects have been produced following exposure of animals by at least one other route and good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting. Not normally a hazard due to non-volatile nature of product Possible risk of irreversible effects.
Ingestion	Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual. Benzimidazole carbamate anthelmintics, when administered in therapeutic doses, have produced allergic reaction (which may be associated with destruction of parasites), raised liver enzyme values,and may be associated with leukopenia and alopecia. Extremely large oral doses may produce intestinal cramps, anorexia, lethargy, pulmonary haemorrhage, oedema, hepatic and epicardial haemorrhage, and nausea, vomiting and diarrhoea. Other symptoms include dizziness, giddiness, tinnitus, insomnia, anxiety, confusion, convulsions, hallucinations and headache. Overdose may produce gastrointestinal symptoms, visual disturbance and psychic alterations. Absorption is generally limited. *Animal studies suggest that this family of drugs may also be teratogenic* A number of benzimidazoles have been shown to also inhibit mammalian tubulin polymerisation and to be aneugenic *in vivo.* Aneugens affect cell division and the mitotic spindle apparatus resulting in loss or gain of whole chromosomes, thereby inducing an "aneuploidy". Mitotic aneuploidy is a characteristic of many types of tumorigenesis (in cancer). Several benzimidazoles have been shown to be genotoxic. Genotoxicity may arise as aneugens may also be clastogens, or may produce clastogenic metabolites. Clastogens increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes.
Skin Contact	Limited evidence exists, or practical experience predicts, that the material either produces inflammation of the skin in a substantial number of individuals following direct contact, and/or produces significant inflammation when applied to the healthy intact skin of animals, for up to four hours, such inflammation being present twenty-four hours or more after the end of the exposure period. Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis. Open cuts, abraded or irritated skin should not be exposed to this material Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.
Eye	Although the liquid is not thought to be an irritant (as classified by EC Directives), direct contact with the eye may produce transient discomfort characterised by tearing or conjunctival redness (as with windburn).
Chronic	Practical experience shows that skin contact with the material is capable either of inducing a sensitisation reaction in a substantial number of individuals, and/or of producing a positive response in experimental animals. Substances that can cause occupational asthma (also known as asthmagens and respiratory sensitisers) can induce a state of specific airway hyper-responsiveness via an immunological, irritant or other mechanism. Once the airways have become hyper-responsive, further exposure to the substance, sometimes even to tiny quantities, may cause respiratory symptoms. These symptoms can range in severity from a runny nose to asthma. Not all workers who are exposed to a sensitiser will become hyper-responsive and it is impossible to identify in advance who are likely to become hyper-responsive. Substances than can cuase occupational asthma should be distinguished from substances which may trigger the symptoms of asthma in people with pre-existing air-way hyper-responsiveness. The latter substances are not classified as asthmagens or respiratory sensitisers Wherever it is reasonably practicable, exposure to substances that can cuase occupational asthma should be prevented. Where this is not possible the primary aim is to apply adequate standards of control to prevent workers from becoming hyper-responsive. Activities giving rise to short-term peak concentrations should receive particular attention when risk management is being considered. Health surveillance is appropriate for all employees exposed or liable to be exposed to a substance which may cause occupational asthma and there should be appropriate consultation with an occupational health professional over the degree of risk and level of surveillance. There is sufficient evidence to provide a strong presumption that human exposure to the material may result in developmental toxicity, generally on the basis of: - clear results in appropriate animal studies where effects have been observed in the absence of marked maternal toxicity, or at around the same dose levels as other toxic effects but which are not secondary non-specific consequences of the other toxic effects. In animal tests, toxic doses of albendazole have resulted in anorexia, lethargy,pulmonary hemorrhage and oedema; hepatic and epicardial hemorrhage. Doses of 10 mg/kg/day albendazole for one month in humans receiving treatment for parasitic infestation has resulted in reversible abnormalities in liver function tests. In animal tests, toxic doses have resulted in anorexia, lethargy, pulmonary hemorrhage and oedema; hepatic and epicardial hemorrhage. In a chronic study in rats, doses of 20 mg/kg/day produced slightly reduced leukocyte and neutrophil counts. In mice degeneration of tubular epithelium of testes was observed following chronic dosing of 400 mg/kg/day. WARNING: Albendazole may cause birth defects, avoid all exposure in pregnancy A number of benzimidazoles have been shown to also inhibit mammalian tubulin polymerisation and to be aneugenic *in vivo.* Aneugens affect cell division and the mitotic spindle apparatus resulting in loss or gain of whole chromosomes, thereby inducing an "aneuploidy". Mitotic aneuploidy is a characteristic of many types of tumorigenesis (in cancer). Several benzimidazoles have been shown to be genotoxic. Genotoxicity may arise as aneugens may also be clastogens, or may produce clastogenic metabolites. Clastogens increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. Sensitisation may result in allergic dermatitis responses including rash, itching, hives or swelling of extremities. Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or

Continued...

	biochemical systems. Possible risk of irreversible effects.

Pyrimide 3-Way Combination Drench for Sheep	**TOXICITY**	**IRRITATION**
	Not Available	Not Available
levamisole hydrochloride	**TOXICITY**	**IRRITATION**
	Oral(Rat) LD50; 180 mg/kg[2]	Not Available
albendazole	**TOXICITY**	**IRRITATION**
	Oral(Mouse) LD50; 1500 mg/kg[2]	Eye (rabbit): non irritating **
EDTA cobalt disodium salt	**TOXICITY**	**IRRITATION**
	Oral(Rat) LD50; 150 mg/kg[1]	Not Available
abamectin	**TOXICITY**	**IRRITATION**
	dermal (rat) LD50: >330 mg/kg[2]	Eye (rabbit): slight *
	Inhalation(Rat) LC50; 1.1 mg/L4h[2]	Skin (rabbit): non irritating*
	Oral(Rat) LD50; 1.5 mg/kg[2]	
sodium selenate, anhydrous	**TOXICITY**	**IRRITATION**
	Inhalation(Rat) LC50; >0.052<=0.51 mg/l4h[1]	Eye: no adverse effect observed (not irritating)[1]
	Oral(Rat) LD50; 1.6 mg/kg[2]	Skin: adverse effect observed (irritating)[1]
Legend:	*1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2.* Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances*	

LEVAMISOLE HYDROCHLORIDE	for tetramisole hydrochloride Intravenous (rabbit) LD50: 15-20 mg/kg Flaccid paralysis, convulsions, dermatitis after systemic exposure recorded. Non-mutagenic in mammals.
ALBENDAZOLE	(-) rat LD50: 1000 mg/kg** Skin (rabbit): non irritating ** Effects on embryo or fetus. ADI: 0.05 mg/kg/day NOEL: 5 mg/kg/day Exposure to the material may result in a possible risk of irreversible effects. The material may produce mutagenic effects in man. This concern is raised, generally, on the basis of appropriate studies using mammalian somatic cells in vivo. Such findings are often supported by positive results from in vitro mutagenicity studies. Asthma-like symptoms may continue for months or even years after exposure to the material ceases. This may be due to a non-allergenic condition known as reactive airways dysfunction syndrome (RADS) which can occur following exposure to high levels of highly irritating compound. Key criteria for the diagnosis of RADS include the absence of preceding respiratory disease, in a non-atopic individual, with abrupt onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. A reversible airflow pattern, on spirometry, with the presence of moderate to severe bronchial hyperreactivity on methacholine challenge testing and the lack of minimal lymphocytic inflammation, without eosinophilia, have also been included in the criteria for diagnosis of RADS. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. Industrial bronchitis, on the other hand, is a disorder that occurs as result of exposure due to high concentrations of irritating substance (often particulate in nature) and is completely reversible after exposure ceases. The disorder is characterised by dyspnea, cough and mucus production. The 2-aminothiazole motif, is a well-recognized structure alert for reactive metabolite (RM) formation and and drug-induced liver injury (DILI). This motif is isoelectric with 2-aminoimidazole (AI) which may similarly be hepatotoxic in certain presentations. Exposure to the material for prolonged periods may cause physical defects in the developing embryo (teratogenesis).
EDTA COBALT DISODIUM SALT	For ethylenediaminetetraacetic acid (EDTA) and its salts: EDTA is a strong organic acid (approximately 1000 times stronger than acetic acid). It has a high affinity for alkaline-earth ions (for example, calcium and magnesium) and heavy-metal ions (for example, lead and mercury). This affinity generally results in the formation of highly stable and soluble hexadentate chelate complexes. EDTA's ability to complex is used commercially to either promote or inhibit chemical reactions, depending on application. EDTA and its salts are expected to be absorbed by the lungs and gastrointestinal tract; absorption through the skin is unlikely. In general, EDTA and its salts are mild skin irritants but considered severe eye irritants. The greatest risk in the human body will occur when the EDTA attempts to scavenge the trace metals used and required by the body. The binding of divalent and trivalent cations by EDTA can cause mineral deficiencies, which seem to be responsible for all of the known pharmacological effects. Sensitivity to the toxic effects of EDTA is, at least in part, related to the deficiency of zinc. Several short term studies, reported no adverse effects from administering doses up to 5% of EDTA and its salts to lab rodents daily and for several weeks. Only diarrhoea and lowered food consumption were reported in animals given 5% disodium EDTA. However, abnormal effects were seen in animals that were fed mineral deficient diets. Abnormal symptoms were observed in male and female rats fed a low mineral diet (0.54% Ca and 0.013%Fe) with the addition of 0%, 0.5%, or 1% disodium EDTA for 205 days. Rats fed a low percent of disodium EDTA in the diet for short term studies with adequate minerals showed no signs of toxicity. Rats fed 0.5% disodium EDTA for 44-52 weeks were without deleterious effects on weight gain, appetite, activity and appearance. Rats fed 1% disodium EDTA with adequate mineral diet for 220 days showed no evidence of dental erosion. EDTA and its salts are eliminated from the body, 95% via the kidneys and 5% by the bile, along with the metals and free ionic calcium which was bound in transit through the circulatory system. Trisodium EDTA was tested in a bioassay for carcinogenicity by the National Cancer Institute. Trisodium EDTA administered to male and female rats at low (3,750 ppm) or high (7,500 ppm) concentrations for 103 weeks produced no compound-related signs of chemical toxicity, and tumor incidence was not related to treatment . EDTA and its salts should not pose a teratogenic concern based on previous studies in lab rodents. Study results indicate no teratogenic effects are likely in lab rodents at doses up to 1000 mg/kg. Adequate minerals in the diet and administration of tap water prevented possible teratogenic effects of EDTA during pregnancy. Teratogenic effects observed in lab rodents were likely due to animals maintained on deionised water and a semi-purified diet, and housed in nonmetallic caging. Infants and children will unlikely be exposed to high concentrations as in lab rodents. Rats given 1250 mg/kg or 1500 mg/kg by gavage exhibited more maternal toxicity than the diet group, but produced only 21% malformations in the offspring at the lower dose. The subcutaneously administration of 375 mg/kg was also maternally toxic, but did not result in malformations in

Continued...

	the offspring. Differences in toxicity and teratogenicity are probably related to absorption differences and interaction with metals. Disodium EDTA ingested during pregnancy is teratogenic in rats at 2% in the diet and greater. The maximum human consumption of EDTA and its salts in foods was reported to be in the order of 0.4 mg/kg/day. Infants and children also generally drink tap water instead of deionised or distilled water. Even if young infants were to be fed some solid food, given the characteristics of EDTA and its salts, residues are not likely to be present at concentrations for potential sensitivity.
ABAMECTIN	Oral (rat) LD50: 8.7-12.8 mg/kg (14 day) * ADI 0.0001 mg/kg Toxicity Class EPA IV Non-mutagenic in the Ames test ADI: 0.4 mg/day *[Manufacturer] Convulsions recorded. No significant acute toxicological data identified in literature search. For avermectins: Technical avermectin exhibits high mammalian acute toxicity. In vertebrates, the effects occur via poisoning of the central nervous system (CNS) through reactions at the receptor for the inhibitory neurotransmitter GABA. The avermectins open the GABAA receptor chloride channel by binding to the GABA recognition site (receptor protein) and act as partial agonists.. Chloride ions then flow into the postsynaptic neuron. This chloride permeability increase can significantly hyperpolarize (make more negative) the membrane potential, which has a dampening effect on nerve impulse firing. There is also a reversible dose-dependent increase in chloride ion permeability in response to very low doses of avermectins. In GABA-insensitive neurons with no inhibitory innervation, the avermectins induce an irreversible increase in chloride ion conductance through interacting with voltage-dependent chloride channels. Avermectin intoxication in mammals begins with hyperexcitability, tremors, and incoordination and later develops into ataxia and coma-like sedation. This is similar to the mode of action of ethanol and barbiturates and benzodiazepine sedatives However, the avermectins are less specific in their action and can affect a variety of other ligand- and voltage-gated chloride channels. The general safety of the avermectins depends on the presence of an intact P-glycoprotein blood-brain barrier Avermectin is not considered to be mutagenic and does not sensitise skin. It is not readily absorbed by mammals and the majority of the residue is excreted in the faeces within 2 days. The 24-month rat chronic feeding/ oncogenicity study and 94-week mouse chronic toxicity oncogenicity study were negative for oncogenic potential. The results of a series of developmental toxicity studies (rat, rabbit, mouse) have been evaluated and showed that avermectin B1 produces developmental toxicity (cleft palate) in the CF1 mouse. Toxicology data were also evaluated for the delta-8,9-isomer of avermectin B1 which is a plant photodegradate that can range between 5 and 20 percent of the residue on/in cottonseed. This isomer possesses avermectin-like toxicological activity. It was concluded that the delta 8,9-isomer also produces developmental toxicity (cleft palate) in mice, but not in rats. In addition to avermectin and its delta 8,9-isomer, toxicology data were also evaluated for the "polar degradates" of avermectin, which constitute a large percentage (up to 70%) of the total residue on cottonseed. Review of the toxicology data indicated that these polar degradates do not possess avermectin-like toxicological activity and for this reason need not be included in the tolerance expression for residues in/on cottonseed. Abamectin (a mixture of avermectin isomers) is a reproductive toxin in laboratory animals at doses which are acutely toxic to the mother. In development toxicity studies with abamectin, cleft palates were seen in mice and rabbits and clubbing of the forepaws was seen in rabbits. The no-observed-adverse-effect-level (NOAEL) for maternal and developmental toxicity in rabbits was 1 mg/kg/day. In CF-1 mice, a strain recognised to be particularly sensitive to avermectins, the NOAEL for maternal toxicity was 0.05 mg/kg/day and the NOAEL for malformations was 0.2 mg/kg/day. Studies show that the sensitivity of a subpopulation of CF-1 mice to avermectins is due to the absence of a transmembrane P-glycoprotein, a significant component of the blood-brain interface that normally acts as a non-selective protective barrier in a wide range of species including humans. CF-1 mice are therefore an unlikely candidate for assessing human risk. No evidence of developmental toxicity was seen in oral studies in rats in the absence of maternal toxicity (NOAEL = 1.6 mg/kg/day). In a rat multigenerational reproduction study, pup toxicity and deaths were seen at 0.4 mg/kg/day (NOAEL = 0.12 mg/kg/day). Neonatal rats are not an appropriate model for assessing human risk in humans because (a) rat milk has a greater fat content than human breast milk and abamectin concentrates in fat; (b) on a weight basis, the neonatal rat consumes significantly greater quantities of milk than the newborn human and(c) the blood brain barrier in rodents is formed post-natally (as evidenced by low P-glycoprotein levels) while in humans this membrane is formed pre-natally. Ivermectin, a close structural analogue, has been used extensively in the treatment of human onchocerciasis at an oral therapeutic dose of 0.2 mg/kg, without serious drug-related effects. Despite its wide usage in animals and humans, ivermectin does dot appear to produce birth defects. Abamectin is non-mutagenic in the Ames test and the micronucleus test. Dietary carcinogenicity studies in mice and rats showed negative results. In a 14-week oral study in monkeys no effects were seen at 0.2, 0.5 or 1.0 mg/kg/day; emesis was seen at 2.0 mg/kg/day; delayed pupillary obstruction at 6 and 8 mg/kg/day and mydriasis at 12 mg/kg/day. In chronic oral toxicity, abamectin produced decreased body weight gain in mice (no-observed-adverse-effect-level (NOAEL) = 1.5 mg/kg/day); tremors in rats (NOAEL = 1.5 mg/kg/day), weight loss, tremors, mydriasis, liver and gall bladder changes and death in dogs (NOAEL = 0.25 mg/kg/day); and emesis, mydriasis and sedation in monkeys (NOAL = 1 mg/kg/day).
SODIUM SELENATE, ANHYDROUS	Eye effects, general anaesthesia, convulsions, muscle weakness, spasticity, cardiac EKG changes, cyanosis, lung tumours, diarrhoea, impaired liver function tests, leumaemia, specific developmental changes, effects on newborn recorded. The substance is classified by IARC as Group 3: **NOT** classifiable as to its carcinogenicity to humans. Evidence of carcinogenicity may be inadequate or limited in animal testing.
ALBENDAZOLE & EDTA COBALT DISODIUM SALT	The following information refers to contact allergens as a group and may not be specific to this product. Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke's oedema. The pathogenesis of contact eczema involves a cell-mediated (T lymphocytes) immune reaction of the delayed type. Other allergic skin reactions, e.g. contact urticaria, involve antibody-mediated immune reactions. The significance of the contact allergen is not simply determined by its sensitisation potential: the distribution of the substance and the opportunities for contact with it are equally important. A weakly sensitising substance which is widely distributed can be a more important allergen than one with stronger sensitising potential with which few individuals come into contact. From a clinical point of view, substances are noteworthy if they produce an allergic test reaction in more than 1% of the persons tested.

Acute Toxicity	✔	**Carcinogenicity**	✘
Skin Irritation/Corrosion	✘	**Reproductivity**	✔
Serious Eye Damage/Irritation	✘	**STOT - Single Exposure**	✘
Respiratory or Skin sensitisation	✔	**STOT - Repeated Exposure**	✘
Mutagenicity	✔	**Aspiration Hazard**	✘

Legend: ✘ *– Data either not available or does not fill the criteria for classification*
✔ *– Data available to make classification*

SECTION 12 Ecological information

Toxicity

Pyrimide 3-Way Combination Drench for Sheep	**Endpoint**	**Test Duration (hr)**	**Species**	**Value**	**Source**
	Not Available	Not Available	Not Available	Not Available	Not Available
levamisole hydrochloride	**Endpoint**	**Test Duration (hr)**	**Species**	**Value**	**Source**

Continued...

	Not Available	Not Available	Not Available	Not Available	Not Available

albendazole

Endpoint	Test Duration (hr)	Species	Value	Source
NOEC(ECx)	48h	Fish	0.022mg/l	4

EDTA cobalt disodium salt

Endpoint	Test Duration (hr)	Species	Value	Source
EC50	72h	Algae or other aquatic plants	>60mg/l	2
EC50	48h	Crustacea	>0.754mg/l	2
EC50(ECx)	48h	Crustacea	>0.754mg/l	2

abamectin

Endpoint	Test Duration (hr)	Species	Value	Source
EC50(ECx)	48h	Crustacea	<0.001mg/l	4
EC50	72h	Algae or other aquatic plants	4.4mg/l	4
LC50	96h	Fish	0.002-0.006mg/L	4
EC50	48h	Crustacea	<0.001mg/l	4
EC50	96h	Algae or other aquatic plants	7.31mg/l	4

sodium selenate, anhydrous

Endpoint	Test Duration (hr)	Species	Value	Source
EC50	48h	Crustacea	0.52-0.63mg/l	4
LC50	96h	Fish	2.1-2.7mg/l	4
NOEC(ECx)	4320h	Fish	<0.005mg/l	2
EC50	96h	Algae or other aquatic plants	12mg/l	4

Legend: *Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 3. EPIWIN Suite V3.12 (QSAR) - Aquatic Toxicity Data (Estimated) 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data*

Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.
DO NOT discharge into sewer or waterways.

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
levamisole hydrochloride	HIGH	HIGH
albendazole	HIGH	HIGH
sodium selenate, anhydrous	HIGH	HIGH

Bioaccumulative potential

Ingredient	Bioaccumulation
levamisole hydrochloride	LOW (LogKOW = 1.84)
albendazole	LOW (LogKOW = 3.1358)
sodium selenate, anhydrous	LOW (LogKOW = -3.1818)

Mobility in soil

Ingredient	Mobility
levamisole hydrochloride	LOW (KOC = 8652)
albendazole	LOW (KOC = 1871)
sodium selenate, anhydrous	LOW (KOC = 48.64)

SECTION 13 Disposal considerations

Waste treatment methods

Product / Packaging disposal

- Containers may still present a chemical hazard/ danger when empty.
- Return to supplier for reuse/ recycling if possible.

Otherwise:

- If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill.
- Where possible retain label warnings and SDS and observe all notices pertaining to the product.
- **DO NOT** allow wash water from cleaning or process equipment to enter drains.
- It may be necessary to collect all wash water for treatment before disposal.
- In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first.
- Where in doubt contact the responsible authority.
- Recycle wherever possible or consult manufacturer for recycling options.
- Consult State Land Waste Authority for disposal.
- Bury or incinerate residue at an approved site.
- Recycle containers if possible, or dispose of in an authorised landfill.

SECTION 14 Transport information

Continued...

Labels Required

	
Marine Pollutant	
HAZCHEM	•3Z

Land transport (ADG)

UN number	3082
UN proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (contains albendazole and abamectin)
Transport hazard class(es)	Class: 9 Subrisk: Not Applicable
Packing group	III
Environmental hazard	Environmentally hazardous
Special precautions for user	Special provisions: 274 331 335 375 AU01 Limited quantity: 5 L

Environmentally Hazardous Substances meeting the descriptions of UN 3077 or UN 3082
are not subject to this Code when transported by road or rail in;
(a) packagings;
(b) IBCs; or
(c) any other receptacle not exceeding 500 kg(L).
- Australian Special Provisions (SP AU01) - ADG Code 7th Ed.

Air transport (ICAO-IATA / DGR)

UN number	3082
UN proper shipping name	Environmentally hazardous substance, liquid, n.o.s. * (contains albendazole and abamectin)
Transport hazard class(es)	ICAO/IATA Class: 9 ICAO / IATA Subrisk: Not Applicable ERG Code: 9L
Packing group	III
Environmental hazard	Environmentally hazardous
Special precautions for user	Special provisions: A97 A158 A197 A215 Cargo Only Packing Instructions: 964 Cargo Only Maximum Qty / Pack: 450 L Passenger and Cargo Packing Instructions: 964 Passenger and Cargo Maximum Qty / Pack: 450 L Passenger and Cargo Limited Quantity Packing Instructions: Y964 Passenger and Cargo Limited Maximum Qty / Pack: 30 kg G

Sea transport (IMDG-Code / GGVSee)

UN number	3082
UN proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (contains albendazole and abamectin)
Transport hazard class(es)	IMDG Class: 9 IMDG Subrisk: Not Applicable
Packing group	III
Environmental hazard	Marine Pollutant
Special precautions for user	EMS Number: F-A , S-F Special provisions: 274 335 969 Limited Quantities: 5 L

Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Continued...

Product name	Group
levamisole hydrochloride	Not Available
albendazole	Not Available
EDTA cobalt disodium salt	Not Available
abamectin	Not Available
sodium selenate, anhydrous	Not Available

Transport in bulk in accordance with the ICG Code

Product name	Ship Type
levamisole hydrochloride	Not Available
albendazole	Not Available
EDTA cobalt disodium salt	Not Available
abamectin	Not Available
sodium selenate, anhydrous	Not Available

SECTION 15 Regulatory information

Safety, health and environmental regulations / legislation specific for the substance or mixture

levamisole hydrochloride is found on the following regulatory lists

Australia Chemicals with non-industrial uses removed from the Australian Inventory of Chemical Substances (old Inventory)
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 4
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6
Australian Inventory of Industrial Chemicals (AIIC)

albendazole is found on the following regulatory lists

Australia Chemicals with non-industrial uses removed from the Australian Inventory of Chemical Substances (old Inventory)
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 4
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6

EDTA cobalt disodium salt is found on the following regulatory lists

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 4
Australian Inventory of Industrial Chemicals (AIIC)
Chemical Footprint Project - Chemicals of High Concern List
International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs
International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Group 2B: Possibly carcinogenic to humans

abamectin is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 4
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6
Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 7
Chemical Footprint Project - Chemicals of High Concern List

sodium selenate, anhydrous is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals
Australian Inventory of Industrial Chemicals (AIIC)
International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs

National Inventory Status

National Inventory	Status
Australia - AIIC / Australia Non-Industrial Use	No (abamectin)
Canada - DSL	No (albendazole; EDTA cobalt disodium salt; abamectin)
Canada - NDSL	No (levamisole hydrochloride; albendazole; EDTA cobalt disodium salt; abamectin; sodium selenate, anhydrous)
China - IECSC	No (abamectin)
Europe - EINEC / ELINCS / NLP	No (abamectin)
Japan - ENCS	No (albendazole; EDTA cobalt disodium salt; abamectin)
Korea - KECI	No (EDTA cobalt disodium salt)
New Zealand - NZIoC	Yes
Philippines - PICCS	No (albendazole; EDTA cobalt disodium salt; abamectin)
USA - TSCA	No (levamisole hydrochloride; albendazole; EDTA cobalt disodium salt; abamectin)
Taiwan - TCSI	Yes
Mexico - INSQ	No (EDTA cobalt disodium salt)
Vietnam - NCI	No (EDTA cobalt disodium salt)
Russia - FBEPH	No (levamisole hydrochloride; albendazole; EDTA cobalt disodium salt; abamectin; sodium selenate, anhydrous)
Legend:	*Yes = All CAS declared ingredients are on the inventory* *No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.*

Continued...

SECTION 16 Other information

Revision Date	17/08/2021
Initial Date	17/08/2021

Other information

Ingredients with multiple cas numbers

Name	CAS No
levamisole hydrochloride	16595-80-5, 14769-73-4
abamectin	71751-41-2, 86753-29-9

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

PC—TWA: Permissible Concentration-Time Weighted Average
PC—STEL: Permissible Concentration-Short Term Exposure Limit
IARC: International Agency for Research on Cancer
ACGIH: American Conference of Governmental Industrial Hygienists
STEL: Short Term Exposure Limit
TEEL: Temporary Emergency Exposure Limit。
IDLH: Immediately Dangerous to Life or Health Concentrations
ES: Exposure Standard
OSF: Odour Safety Factor
NOAEL :No Observed Adverse Effect Level
LOAEL: Lowest Observed Adverse Effect Level
TLV: Threshold Limit Value
LOD: Limit Of Detection
OTV: Odour Threshold Value
BCF: BioConcentration Factors
BEI: Biological Exposure Index
AIIC: Australian Inventory of Industrial Chemicals
DSL: Domestic Substances List
NDSL: Non-Domestic Substances List
IECSC: Inventory of Existing Chemical Substance in China
EINECS: European INventory of Existing Commercial chemical Substances
ELINCS: European List of Notified Chemical Substances
NLP: No-Longer Polymers
ENCS: Existing and New Chemical Substances Inventory
KECI: Korea Existing Chemicals Inventory
NZIoC: New Zealand Inventory of Chemicals
PICCS: Philippine Inventory of Chemicals and Chemical Substances
TSCA: Toxic Substances Control Act
TCSI: Taiwan Chemical Substance Inventory
INSQ: Inventario Nacional de Sustancias Químicas
NCI: National Chemical Inventory
FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances